1 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7-30, doi:10.3322/caac.21590 (2020).
2 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394-424, doi:10.3322/caac.21492 (2018).
3 Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945-956, doi:10.1016/S0140-6736(15)01224-6 (2016).
4 Lowes, L. E. & Allan, A. L. Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition. Adv Clin Chem 83, 121-181, doi:10.1016/bs.acc.2017.10.004 (2018).
5 Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13, 920-928, doi:10.1158/1078-0432.CCR-06-1695 (2007).
6 Scher, H. I. et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10, 233-239, doi:10.1016/S1470-2045(08)70340-1 (2009).
7 Wu, S. et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One 10, e0123976, doi:10.1371/journal.pone.0123976 (2015).
8 Qi, L. N. et al. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Cancer Res 78, 4731-4744, doi:10.1158/0008-5472.CAN-17-2459 (2018).
9 Burinaru, T. A. et al. Detection of Circulating Tumor Cells Using Microfluidics. ACS Comb Sci 20, 107-126, doi:10.1021/acscombsci.7b00146 (2018).
10 Poveda, A. et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 122, 567-572, doi:10.1016/j.ygyno.2011.05.028 (2011).
11 Allard, W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10, 6897-6904, doi:10.1158/1078-0432.CCR-04-0378 (2004).
12 Chen, Y. et al. Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci Rep 9, 7084, doi:10.1038/s41598-019-43572-1 (2019).
13 Guan, X. et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond) 39, 1, doi:10.1186/s40880-018-0346-4 (2019).
14 Kim, S. I. et al. Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. Cancer Res Treat 51, 1144-1155, doi:10.4143/crt.2018.508 (2019).
15 Balachandran, V. P., Gonen, M., Smith, J. J. & DeMatteo, R. P. Nomograms in oncology: more than meets the eye. Lancet Oncol 16, e173-180, doi:10.1016/S1470-2045(14)71116-7 (2015).
16 Gerestein, C. G. et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116, 372-380, doi:10.1111/j.1471-0528.2008.02033.x (2009).
17 Bookman, M. A. Can we predict who lives long with ovarian cancer? Cancer 125 Suppl 24, 4578-4581, doi:10.1002/cncr.32474 (2019).
18 Budd, G. T. et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 12, 6403-6409, doi:10.1158/1078-0432.CCR-05-1769 (2006).
19 Hayes, D. F. et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12, 4218-4224, doi:10.1158/1078-0432.CCR-05-2821 (2006).
20 Judson, P. L. et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol 91, 389-394, doi:10.1016/j.ygyno.2003.08.004 (2003).
21 Fan, T., Zhao, Q., Chen, J. J., Chen, W. T. & Pearl, M. L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 112, 185-191, doi:10.1016/j.ygyno.2008.09.021 (2009).
22 Guo, W. et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res 20, 4794-4805, doi:10.1158/1078-0432.CCR-14-0251 (2014).
23 Cham, S. et al. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. Am J Obstet Gynecol 220, 571 e571-571 e578, doi:10.1016/j.ajog.2019.02.019 (2019).
24 Duska, L. R., Java, J. J., Cohn, D. E. & Burger, R. A. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecol Oncol 139, 221-227, doi:10.1016/j.ygyno.2015.08.011 (2015).
25 Lee, C. K. et al. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. Eur J Cancer 117, 99-106, doi:10.1016/j.ejca.2019.05.029 (2019).
26 Bogani, G. et al. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. J Gynecol Oncol 29, e40, doi:10.3802/jgo.2018.29.e40 (2018).
27 Adams, D. L., Alpaugh, R. K., Tsai, S., Tang, C. M. & Stefansson, S. Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci Rep 6, 33488, doi:10.1038/srep33488 (2016).
28 Zhao, X. H. et al. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice. World J Gastroenterol 25, 138-150, doi:10.3748/wjg.v25.i1.138 (2019).
29 Iasonos, A., Schrag, D., Raj, G. V. & Panageas, K. S. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26, 1364-1370, doi:10.1200/JCO.2007.12.9791 (2008).
30 Harrell, F. E., Jr., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15, 361-387, doi:10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 (1996).
31 Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10, 7252-7259, doi:10.1158/1078-0432.CCR-04-0713 (2004).